SigmaAldrich News

Roche Holding AG teamed up with Sigma-Aldrich Corp to make an unsuccessful bid for Life Technologies Corp earlier this year, people familiar with the matter said.

The company offers biochemical, organic chemical products, kits and services. Its products and services find applications in scientific research such as genomic and proteomic research, diagnosis of disease, pharmaceutical development, biotechnology, as well as key components in diagnostics, pharmaceutical, and high technology manufacturing.

Sigma-Aldrich Corp. on Monday launched of new search engine on its website that gives researchers access to peer-reviewed articles and abstract information.

Sigma-Aldrich Corp announced a quarterly dividend on Tuesday, May 7th, ARN reports.

Shares of Sigma-Aldrich Corp opened at 78.88 on Tuesday. Sigma-Aldrich Corp has a one year low of $66.52 and a one year high of $79.32. The stock's 50-day moving average is currently $77.20. The company has a market cap of $9.492 billion and a P/E ratio of 20.65. Sigma-Aldrich Corp last announced its earnings results on Thursday, April 25th.

When Texans do anything, it tends to be big. Case in point, Texan Guru Donald Yacktman of Yacktman Asset Management, and his funds bought BIG in the first quarter of 2013, according to GuruFocus Real Time Picks .

Renowned value investor Donald Yacktman just reported his first quarter holdings.

Why might an upstanding firm like Sigma-Aldrich do this? For the same reason any other company might: to make the numbers.

A replay of the meeting and the presentation slides will be posted on the Company's website following the meeting.

Only one new stock met Austin, Texas-based investor Donald Yacktman 's rigorous standards for inclusion in his funds this past quarter: Sigma-Aldrich Corporation , a stock whose price has been going up fairly steadily since 2009.

Sigma-Aldrich Corporation Reports Q1 2013 Sales And EPS of $675 Million and $1.01, Respectively, Both Record Quarterly Highs.

Sigma-Aldrich Corp. 's first-quarter net income rose 4.3% although most of the sales growth in its SAFC commercial unit was led by the life science products and services business.

On April 22, after the close of trading, Illumina released its Q1 2013 earnings, delivering another solid quarter in the face of perceived uncertainty.